Tampa, FL. August 21, 2024 – Newswire – CTT Pharmaceuticals Holdings, Inc. (OTC: CTTH), is pleased to announce that the registered PCAOB Accounting Firm of DiPiazza, LaRocca, Heeter & Co., led by audit partne Matthew Stewart have successfully completed the 2 year audit of CTT Pharma. This comprehensive audit
included the review of CiT’s bank statements, patents, contracts and share allocation over the past 2 years and has received the necessary approvals to allow CIT Pharma to be in compliance with PCAOB Regulations. The
PCAOB Audit Letter and Audited Financials for 2022 and 2023 have been successful uploaded to the Olf Markets Website for anyone to view. This important milestone will allow CTT to uplist at any point now and should also give existing shareholders, future shareholders, investment firms and potential partners including the U.S. Government and other partnerships that may arise the necessary confidence in our management tear that on a day to day basis CTT is functioning at the highest level of integrity.

The Public Company Accounting Oversight Board protects investors and other stakeholders of public companies by ensuring that the auditor of a company’s financial statements has followed a set of strict guidelines to minimize audit risk. The PCAOB is a non-profit organization that regulates auditors of publicly traded companies and oversees the audits of public companies, brokers, and dealers registered with the U.S. Securities and Exchange Commission (SEC), Ran Khouri. CFO of CIT Pharma. stated. “This PCAOB Audit was very extensive and should ensure a level of confidence amongst existing and future shareholders, while allowing C I the ability to uplist to the OlCQB. Furthermore, I will continue to work hard to gain traction with the U.S. Government for the necessary grants and loans to help launch our Nicotine Strips as the tobacco industry is long overdue for CT’s technology, which would be a low dose, fast dissolving nicotine strip. The market currently offers cigarettes, vaping and oral deliverables that stay in the mouth for extended periods of time and have significantly higher amounts of nicotine in these products. There’s 480,000 Americans that will die this year from the effects of smoking or the equivalent of 1300 Americans losing their life daily. I look forward to continue the fight to not only help this industry but also make an impact on many other industries using our patented technology.

About CT Pharmaceuticals Holdings, Inc.
CIT has granted and pending patents for our technology in the United States, Europe, Canada and several other countries around the world that allow for many drugs to be put on dissolvable strips and other oral products including but not limited to Pharmaceuticals, Nicotine, Liraglutide, Vitamins, and Caffeine. This patented technology allows for better bioavailability/absorption, quick onset, and the ability to make low dose dissolvable
strips.

Company Info: Phone: 813-606-0060 Twitter/X: @CTT Pharmi

Tampa, Florida, United States – The Newswire – March 28, 2023 – CTT Pharmaceutical Holdings, Inc. (OTC:CTTH) is pleased to announce David Paton has become a Senior Advisor for CTT Pharma effective April 1, 2023.

Mr. Paton previously worked for British American Tobacco (BAT) for 11 years in several Vice-President level innovation roles. Amongst these, David was Head of Product Development for Tobacco Heating Products, where he led the development through launch of glo in 2016. During his last four years at BAT, David served as Head of Discovery and Head of Open Innovation, while also managing numerous technology partnerships with start-up and scale-up companies. David also spent 10 years at Kimberly-Clark as a Senior Scientist and Technical Consultant, giving him more than two decades of experience in product development and R&D Leadership roles. David Paton stated, “I am thrilled to have been appointed as a Senior Advisor for CTT. I cannot wait to contribute my expertise and help drive the company towards success through their exciting product plans.”

Ryan Khouri, CEO of CTT Pharma, stated “David’s years of work at British American Tobacco and Kimberly-Clark in product development and R&D leadership roles will provide me with valuable insight into future development and partnerships for our patented technology. I’m excited that he has joined CTT Pharma and look forward to future opportunities.

CTT will continue to update shareholders as more news becomes available.

About CTT Pharma

CTT’s patented dissolvable strips enter the bloodstream once dissolved in the mouth, bypassing the lungs and digestive tract, allowing for better absorption, faster onset, as fast as an injection, and the ability to combine actives. This technology can be used for many industries including but not limited to Pharmaceuticals, Nicotine, and Vitamins. Furthermore, CTT has the ability to create smoke-free products with less milligrams of a desired drug needed on a strip than traditional oral delivery methods because of higher bioavailability and absorption.